Further characterization of the CD4+ T-cell responses is needed in order to discern possible pathogenic links to the development of uremic cardiomyopathy, evaluate their role as novel biomarkers of disease and subsequently examine the effects of immunomodulation on the CKD-related myocardial remodeling. The gene discussed is CD4; the disease is chronic kidney disease.